The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

Janis M. Taube, Guray Akturk, Michael Angelo, Elizabeth L. Engle, Sacha Gnjatic, Shirley Greenbaum, Noah F. Greenwald, Cyrus V. Hedvat, Travis J. Hollmann, Jonathan Juco, Edwin R. Parra, Marlon C. Rebelatto, David L. Rimm, Jaime Rodriguez-Canales, Kurt A. Schalper, Edward C. Stack, Cláudia S. Ferreira, Konstanty Korski, Ana Lako, Scott J. RodigEmanuel Schenck, Keith E. Steele, Michael J. Surace, Michael T. Tetzlaff, Katharina Von Loga, Ignacio I. Wistuba, Carlo B. Bifulco

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives The interaction between the immune system and tumor cells is an important feature for the prognosis and treatment of cancer. Multiplex immunohistochemistry (mIHC) and multiplex immunofluorescence (mIF) analyses are emerging technologies that can be used to help quantify immune cell subsets, their functional state, and their spatial arrangement within the tumor microenvironment. Methods The Society for Immunotherapy of Cancer (SITC) convened a task force of pathologists and laboratory leaders from academic centers as well as experts from pharmaceutical and diagnostic companies to develop best practice guidelines for the optimization and validation of mIHC/mIF assays across platforms. Results Representative outputs and the advantages and disadvantages of mIHC/mIF approaches, such as multiplexed chromogenic IHC, multiplexed immunohistochemical consecutive staining on single slide, mIF (including multispectral approaches), tissue-based mass spectrometry, and digital spatial profiling are discussed. Conclusions mIHC/mIF technologies are becoming standard tools for biomarker studies and are likely to enter routine clinical practice in the near future. Careful assay optimization and validation will help ensure outputs are robust and comparable across laboratories as well as potentially across mIHC/mIF platforms. Quantitative image analysis of mIHC/mIF output and data management considerations will be addressed in a complementary manuscript from this task force.

Original languageEnglish (US)
Article numbere000155
JournalJournal for immunotherapy of cancer
Volume8
Issue number1
DOIs
StatePublished - May 15 2020

Keywords

  • image analysis
  • immunology
  • oncology
  • tumors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation'. Together they form a unique fingerprint.

Cite this